{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:36:11Z","timestamp":1793954171248,"version":"4.8.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health, Labour and Welfare of Japan"},{"name":"Ministry of Health, Labour and Welfare of Japan"},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Society for the Promotion of Science for Scientific Research"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2014.11.015","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T18:57:29Z","timestamp":1416596249000},"page":"1975-1985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan"],"prefix":"10.1016","volume":"34","author":[{"given":"Hiroyuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.11.015_bib0005","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.vaccine.2014.04.023","article-title":"Polio vaccines: WHO position paper, January 2014\u2014recommendations","volume":"32","author":"World Health Organization","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0010","series-title":"Polio Eradication and Endgame Strategic Plan 2013\u20132018","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0015","series-title":"Call for expressions of interest (EoI)\u2014developing Sabin-inactivated polio vaccine (sIPV)","author":"Global Polio Eradication Initiative","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0020","series-title":"WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biologicals.2006.03.003","article-title":"Post-eradication poliovirus facility-associated community risks","volume":"34","author":"Dowdle","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0030","first-page":"759","article-title":"On the Hein Mwdin's disease","volume":"125","author":"Hirai","year":"1910","journal-title":"Jikazasshi"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0035","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0040","first-page":"1","article-title":"Poliomyelitis in Japan","volume":"3","author":"Kono","year":"1960","journal-title":"Annu Rep Inst Virus Res, Kyoto Univ"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0045","first-page":"206","article-title":"Poliomyelitis in Japan","volume":"45","author":"Paul","year":"1947","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0050","first-page":"129","article-title":"Poliomyelitis in Japan during the period 1962\u201368 after the introduction of mass vaccination with Sabin vaccine","volume":"49","author":"Takatsu","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.7883\/yoken1952.19.277","article-title":"Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children","volume":"19","author":"Vaccine Administration Subcommittee","year":"1966","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0060","series-title":"Vaccines","first-page":"598","article-title":"Poliovirus vaccine-live","author":"Sutter","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0065","first-page":"547","article-title":"Characterization of poliovirus isolates in Japan after the mass vaccination with live oral poliomyelitis vaccine (Sabin)","volume":"48","author":"Tagaya","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0070","first-page":"178","article-title":"Parameters for differentiating vaccine-derived and wild poliovirus strains","volume":"24","author":"Nakano","year":"1978","journal-title":"Prog Med Virol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0075","first-page":"135","article-title":"Studies on the antigenic serodifferentiation of poliovirus strains","volume":"16","author":"Kitahara","year":"1963","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1348-0421.1987.tb03093.x","article-title":"Antigenic and biochemical characterization of poliovirus type 1 isolates","volume":"31","author":"Hara","year":"1987","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1348-0421.1983.tb02939.x","article-title":"Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin","volume":"27","author":"Hara","year":"1983","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1348-0421.1981.tb00059.x","article-title":"Structural proteins of poliovirus type 2 isolates","volume":"25","author":"Yoneyama","year":"1981","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7883\/yoken1952.48.61","article-title":"Characterization of a wild poliovirus type 3 isolated Japan in 1993","volume":"48","author":"Yoneyama","year":"1995","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00443199","article-title":"Paralytic poliomyelitis in a child with agammaglobulinemia","volume":"132","author":"Abo","year":"1979","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/IAI.37.1.46-53.1982","article-title":"Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients","volume":"37","author":"Yoneyama","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1348-0421.1981.tb00095.x","article-title":"Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration","volume":"25","author":"Hara","year":"1981","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0120","series-title":"Country progress report on maintaining polio-free status for the 18th regional commission for the certification of poliomyelitis eradication in the Western Pacific","first-page":"1","author":"National Committee for the Certification of Poliomyelitis Eradication of Japan","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0125","first-page":"80","article-title":"Isolation of vaccine-derived strain in epodemiological surveillnace of poliovirus","volume":"28","author":"Iwai","year":"2005"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0130","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu164","article-title":"Maintaining polio-free certification in the World Health Organization Western Pacific Region for over a decade","author":"Adams","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0135","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.vaccine.2014.02.093","article-title":"Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO's Western Pacific Region","volume":"32","author":"Hennessey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0140","first-page":"1479","article-title":"A second WHO region declared polio-free","volume":"78","author":"Maurice","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0887-8994(00)00167-3","article-title":"Acute disseminated encephalomyelitis associated with poliomyelitis vaccine","volume":"23","author":"Ozawa","year":"2000","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/00365540110027204","article-title":"Polio vaccine virus-associated meningoencephalitis in an infant with transient hypogammaglobulinemia","volume":"33","author":"Inaba","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tmaid.2010.05.004","article-title":"Japanese vaccinations and practices, with particular attention to polio and pertussis","volume":"9","author":"Nakano","year":"2011","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0160","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7883\/yoken.63.216","article-title":"A case of paralytic poliomyelitis associated with poliovirus vaccine strains in hokkaido, Japan","volume":"63","author":"Miyoshi","year":"2010","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0165","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10156-010-0065-5","article-title":"Vaccine-associated paralytic poliomyelitis in an infant with perianal abscesses","volume":"16","author":"Higashigawa","year":"2010","journal-title":"J Infect Chemother."},{"key":"10.1016\/j.vaccine.2014.11.015_bib0170","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1442-200X.2010.03132.x","article-title":"Vaccine-associated paralytic poliomyelitis in a non-immunocompromised infant","volume":"52","author":"Asahina","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7883\/yoken.JJID.2008.100","article-title":"Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000","volume":"61","author":"Hao","year":"2008","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0180","series-title":"A conference material\u2014The fist conference on smooth promotion for IPV introduction","first-page":"16","article-title":"Labour and Welfare","author":"Ministry of Health","year":"2011"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0185","first-page":"45","article-title":"Developmemnt of Sabin strain-derived inactivated poliovirus vaccine in Japan","volume":"26","author":"Yamazaki","year":"2011","journal-title":"BIO Clinica"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biologicals.2006.02.010","article-title":"Development of inactivated poliovirus vaccine derived from Sabin strains","volume":"34","author":"Simizu","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0195","first-page":"163","article-title":"Progress with inactivated poliovirus vaccines derived from the Sabin strains","volume":"105","author":"Doi","year":"2001","journal-title":"DevBiol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0200","first-page":"248","article-title":"Development and clinical evaluation on the enhanced-potency inactivated poliovirus vaccine made from the Sabin strains","volume":"27","author":"Abe","year":"1999","journal-title":"Clin Virol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2222\/jsv.36.125","article-title":"Preparation of inactivated poliomyelitis vaccine with attenuated Sabin strains","volume":"36","author":"Abe","year":"1986","journal-title":"Uirusu"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0210","series-title":"WHO global action plan for laboratory containment of wild polioviruses","author":"World Health Organization","year":"2004"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0215","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(00)00350-9","article-title":"Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells","volume":"19","author":"Horie","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0220","series-title":"A conference material\u2014the fist conference on smooth promotion for IPV introduction","first-page":"7","article-title":"Labour and Welfare","author":"Ministry of Health","year":"2011"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0225","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1016\/j.vaccine.2007.07.060","article-title":"Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains","volume":"25","author":"Tano","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0230","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1099\/vir.0.19088-0","article-title":"Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains","volume":"84","author":"Martin","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0235","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0264-410X(98)00409-5","article-title":"Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains","volume":"17","author":"Kersten","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/biol.1997.0100","article-title":"Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site","volume":"25","author":"Sawyer","year":"1997","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/biol.1993.1070","article-title":"Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains","volume":"21","author":"Sawyer","year":"1993","journal-title":"Biologicals"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2014.11.015_bib0250","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1099\/0022-1317-74-4-685","article-title":"Antigenic structure of poliovirus in inactivated vaccines","volume":"74","author":"Ferguson","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0255","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0260","doi-asserted-by":"crossref","first-page":"e83374","DOI":"10.1371\/journal.pone.0083374","article-title":"Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals","volume":"8","author":"Thomassen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0265","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0270","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/506949","article-title":"Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine","volume":"194","author":"Dragunsky","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0275","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/424524","article-title":"Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy","volume":"190","author":"Dragunsky","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0280","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1016\/j.vaccine.2014.07.065","article-title":"A national reference for inactivated polio vaccine derived from Sabin strains in Japan","volume":"32","author":"Shirato","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0285","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biologicals.2012.12.004","article-title":"Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine","volume":"41","author":"Sato","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jit155","article-title":"Phase II and III clinical studies of Diphtheria\u2013Tetanus\u2013Acellular Pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV)","volume":"208","author":"Okada","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0295","first-page":"72","article-title":"Efficacy and safety of absorbed acellular pertussis\u2013diphtheria\u2013tetanus\u2013Sabin strains derivd inactivated poliovirus combination vaccine","volume":"28","author":"Ogawa","year":"2013","journal-title":"BIO Clin"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0300","series-title":"Review report\u2014quattrovac subcutaneous injection syringe","author":"Pharmaceuticals and Medical Devices Agency","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0305","series-title":"Review report\u2014tetrabik subcutaneous injection syringe","author":"Pharmaceuticals and Medical Devices Agency","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0310","series-title":"Vaccines","first-page":"573","article-title":"Poliovirus vaccine-inactivated","author":"Vidor","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0315","series-title":"Fact sheet for poliovirus vaccine","author":"National Institute of Infectious Diseases","year":"2010"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0320","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.vaccine.2008.07.026","article-title":"World wide experience with inactivated poliovirus vaccine","volume":"26","author":"Bonnet","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0325","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","article-title":"Vaccine policy changes and epidemiology of poliomyelitis in the United States","volume":"292","author":"Alexander","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0330","unstructured":"Sanofi Pasteur. [in Japanese] IMOVAX POLIO subcutaneous. \u3008http:\/\/www.info.pmda.go.jp\/shinyaku\/P201200053\/650274000_22400AMX00684000_B100_2.pdf\u3009."},{"key":"10.1016\/j.vaccine.2014.11.015_bib0335","series-title":"A survey of vaccination coverage by routine OPV immunization in the spring of 2012","article-title":"Labour and welfare","author":"Ministry of Health","year":"2012"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0340","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7883\/yoken.JJID.2002.101","article-title":"Development of vaccination policy in Japan: current issues and policy directions","volume":"55","author":"Nakatani","year":"2002","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0345","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1016\/j.vaccine.2012.04.026","article-title":"Current issues with the immunization program in Japan: can we fill the \u201cvaccine gap\u201d?","volume":"30","author":"Saitoh","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0350","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0140-6736(12)60232-3","article-title":"Vaccine-associated paralytic poliomyelitis in Japan","volume":"379","author":"Hosoda","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0355","series-title":"On the immunization rates in JFY 2012","article-title":"Labour and Welfare","author":"Ministry of Health","year":"2014"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0360","first-page":"766","article-title":"Imported inactibated polio vaccine use in Kobe city Nihon Shonika Gakkai Zasshi","volume":"117","author":"Fujioka","year":"2013","journal-title":"J Jpn Pediatr Soc"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0365","first-page":"1052","article-title":"A survey of the number of immunization with inctibvated poliovius vaccine; The survey results in 2011","volume":"141","author":"Takayama","year":"2012","journal-title":"J Jpn Med Assoc"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0370","first-page":"609","article-title":"Cummulative vaccination covrrage of oral poliovirus vaccine and inactivated poliovirus vaccine obtained by the nationwide survey in 2013","volume":"143","author":"Takayama","year":"2014","journal-title":"J Jpn Med Assoc"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0375","series-title":"Status of polio immunization and prevalence of antibodies against polioviruses\u2014from a NESVPV survey in 2013","first-page":"18","article-title":"Labour and welfare","author":"Ministry of Health","year":"2014"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0380","series-title":"Country progress report on maintaining polio-free status for the 19th Regional Commission for the certification of poliomyelitis eradication in the Western Pacific","first-page":"1","author":"National Committee for the Certification of Poliomyelitis Eradication of Japan","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0385","series-title":"Squarekids subcutaneous injection syringe","author":"Pharmaceuticals and Medical Devices Agency","year":"2014"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0390","series-title":"Quadrivalent vaccine TAK-361S enters into phase II clinical trials in Japan","author":"Takeda Pharmaceutical Company Limited","year":"2011"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0395","series-title":"Immunogenicity and safety of OPV, IPV, and DPT-IPV in terms of interchangeably","article-title":"Labour and Welfare","author":"Ministry of Health","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0400","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00006454-198811000-00003","article-title":"Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey","volume":"7","author":"Murph","year":"1988","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0405","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0410","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults","volume":"31","author":"Verdijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0415","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0420","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1099\/0022-1317-83-5-1107","article-title":"Prevalence of vaccine-derived polioviruses in the environment","volume":"83","author":"Yoshida","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0425","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(00)02868-3","article-title":"Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan","volume":"356","author":"Yoshida","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0430","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/AEM.66.11.5087-5091.2000","article-title":"Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture","volume":"66","author":"Matsuura","year":"2000","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0435","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(13)62331-4","article-title":"Polio lessons 2013: Israel, the West Bank, and Gaza","volume":"382","author":"Tulchinsky","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0440","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/502601a","article-title":"Polio risk looms over Europe","volume":"502","author":"Butler","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0445","doi-asserted-by":"crossref","first-page":"20708","DOI":"10.2807\/1560-7917.ES2014.19.7.20708","article-title":"Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013","volume":"19","author":"Manor","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0450","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jviromet.2013.10.004","article-title":"Development of real-time PCR to detect oral vaccine-like poliovirus and its application to environmental surveillance","volume":"195","author":"Iwai-Itamochi","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0455","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(05)66386-6","article-title":"Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand","volume":"366","author":"Huang","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0460","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. Efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0465","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/aje\/kwt203","article-title":"The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting","volume":"178","author":"Mangal","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0470","doi-asserted-by":"crossref","first-page":"e1002599","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0475","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.vaccine.2013.12.025","article-title":"Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine","volume":"32","author":"Sun","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0480","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: A phase I Trial in healthy adults in Cuba","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0485","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4155\/ppa.12.70","article-title":"Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains","volume":"1","author":"Hamidi","year":"2012","journal-title":"Pharm Patent Analyst"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0490","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erv.11.51","article-title":"Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains","volume":"10","author":"Verdijk","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0495","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0500","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0505","series-title":"WHO technical working group meeting on revision of the WHO recommen-dations for the production and control of inactivated poliomyelitis vaccines: TRS no. 910, Annex 1","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0510","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7883\/yoken.52.146","article-title":"Genetic analysis of wild polioviruses towards the eradication of poliomyelitis from the Western Pacific Region","volume":"52","author":"Hagiwara","year":"1999","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0515","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1473-3099(13)70330-X","article-title":"Surveillance of hand, foot, and mouth disease for a vaccine","volume":"14","author":"Shimizu","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0520","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0140-6736(13)60286-X","article-title":"Enterovirus 71 encephalitis: a new vaccine on the horizon?","volume":"381","author":"Pallansch","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00006454-200101000-00013","article-title":"Immunologic correlates of protection induced by vaccination","volume":"20","author":"Plotkin","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0530","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.11.015_bib0540","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(12)61764-4","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:26:36Z","timestamp":1747167996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14015400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":108,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X14015400"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}